Drugs

My Holistic Honey c/o Shenzhen Qanhai Wanb Express Supply Chain Co., LTD

FDA issued a warning letter to My Holistic Honey c/o Shenzhen Qanhai Wanb Express Supply Chain Co., LTD (Thousand Oaks, CA, United States) on Aug 25, 2025. Subject: Unapproved New Drugs, Ophthalmic Drug Products.

From the letter: “Based on our review, this product is an unapproved new drug under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a).”

Thousand Oaks, CA, United StatesIssued Aug 25, 2025Posted Sep 2, 2025No close-out recorded

At a glance

What a reviewer notes before reading: findings, citations, the response deadline and what the letter warns of.

Violations
3 findings · 1 issue type
Cited
No CFR or ISO section
Response due
15 working days after receipt of this letter
FDA asks for
4 actions
Named as possible actions
Seizure, injunction
Issued by
Center for Drug Evaluation and Research
Published status
No close-out recorded

AI assisted findings

Model-assisted reading of each issue. Open one to see the FDA text it comes from, and check it against the full letter.

01Labeling, claims & marketingThe product is an unapproved new drug marketed without an FDA-approved application.
Based on our review, this product is an unapproved new drug under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a).
02Labeling, claims & marketingThe product lacks general recognition of safety and effectiveness for its intended uses.
Your “Holistic Honey EYE DROP” is not generally recognized as safe and effective (GRASE) for its above referenced uses and, therefore, this product is a “new drug” under section 201(p) of the FD&C Act, 21 U.S.C. 321(p).
03Labeling, claims & marketingNo FDA-approved application exists for the product.
There is no FDA-approved application pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, in effect for this product.

What FDA requested

  • Notify FDA in writing within fifteen working days of corrective steps taken.
  • Include explanation of each step to prevent recurrence and related documentation.
  • Provide reasoning and supporting information if product believed not in violation.
  • State reason for delay and time to complete correction if not within fifteen days.

FDA Warning Letter

25 paragraphs · 1 section

Text as published on FDA.gov, retrieved Sep 8, 2026. Layout added for reading; the wording is FDA’s. View on FDA.gov (opens in a new tab)

DatedAugust 25, 2025
Sent toRE: 712052
AddressedDear Bingbing Feng

1Letter text

19 paragraphs

This letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your product label and your website at the Internet address https://myholistichoney.com/ in July 2025. The FDA has observed that your website offers “Holistic Honey EYE DROP” (also referred to on your website as “Jimerito Honey Eye Drops”) for sale in the United States. Based on our review, this product is an unapproved new drug under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a). As explained further below, introducing or delivering this product for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).

Your “Holistic Honey EYE DROP” product is especially concerning from a public health perspective. Ophthalmic drug products, which are intended for administration into the eyes, in general pose a greater risk of harm to users because the route of administration for these products bypasses some of the body’s natural defenses.

Based on a review of your product label and website, your “Holistic Honey EYE DROP” is a drug under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and/or intended to affect the structure or any function of the body. Examples of claims that provide evidence of the intended use of this product as a drug include, but may not be limited to, the following:

From your product label:

“HOLISTIC HONEY EYE DROP OPTIMAL VISION”

“It can quickly releve [sic] eye dryness and fatigue and restore eye comfort.”

“Noticeable relief & soothing comfortMy optometrist recommended Holistic Honey for my chronic dry eye condition, and I'm so glad they did. I finally have relief without having to rely on prescription medications!”

“Naturally promotes healing, reduces inflammation, and soothes irritation.”

“Fight Off Eye Fatigue InstantlyProvides immediate comfort & moisture to tired, strained eyes, making them feel refreshed & alert.”

“Give Your Eyes a Natural BoostCrafted with natural ingredients to help your eyes feel their best. It addresses dryness, irritation, and discomfort.”

“Experience Newfound ClarityBy providing essential hydration and lubrication to your eyes.”

“Supports Overall Eye ComfortSupports healthy blood flow and helps maintain comfortable vision.”

“Modern Life Takes a Toll on Your Eyes. Holistic Honey Fights Back.Our eyes work hard in today's digital world, and many of us experience dryness, strain, and discomfort—issues that can contribute to more serious conditions like cataracts or glaucoma over time. Holistic Honey is crafted with the power of nature (honey!) to address these very issues.

Unlike traditional eye drops, Holistic Honey goes beyond just moisture. They provide a natural solution to promote healthier, more comfortable eyes and help reduce the risk of long-term vision problems.”

Your “Holistic Honey EYE DROP” is not generally recognized as safe and effective (GRASE) for its above referenced uses and, therefore, this product is a “new drug” under section 201(p) of the FD&C Act, 21 U.S.C. 321(p). With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a). There is no FDA-approved application pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, in effect for this product. Accordingly, the introduction or delivery for introduction into interstate commerce of these products violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).

The violations cited in this letter are not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.

This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.

Please notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your product is not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction.

Your response should be sent to U.S. Food and Drug Administration, CDER/OC/Office of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov. Please include your firm name and the unique identifier “712052” in the subject line of the email.

Sincerely,/S/

Tina Smith, M.S.Captain, U.S. Public Health ServiceDirectorOffice of Unapproved Drugs and Labeling ComplianceOffice of ComplianceCenter for Drug Evaluation and ResearchFood and Drug Administration

Citations and trends

Each 21 CFR section, ISO 13485 clause and issue type in this letter, how often it appears across all letters, and its trend by the year FDA issued the letters. 2026 runs to Nov 3, 2026, compared with the same dates last year. Select a row or a bar to see those letters in Letters. As cited in this historical letter, not a statement of current requirements.

This letter cites no 21 CFR section or ISO 13485 clause.

Issue types

Record details

Issuing center
Center for Drug Evaluation and Research
Issuing office
Center for Drug Evaluation and Research
Location
Thousand Oaks, CA, United States
Letter posted date
Sep 2, 2025
Letter issue date
Aug 25, 2025
Addressed to
Not recorded
Inspection dates
Not recorded
Response window
15 working days after receipt of this letter
Read the source clause
Please notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to correct any violations.
Record length
841 words · 0 recorded redactions
Published status
No published close-out
Original letter
View on FDA.gov (opens in a new tab)
Dataset last checked
Nov 11, 2026 · How this is built

A response window is not a calculated due date. Source excerpts are selected passages. Finding interpretations and categories are model-assisted. Verify the original letter before relying on a finding.

See the pattern across 1,707 lettersFind letters like this →
Keep exploring

More drug letters

Recent records for the same product type. Your previous filters remain available when you return.

Keep exploring

Find letters like this →
For regulated teams

Put this kind of reading to
work on your own records.

Botable builds and runs a custom AI layer around the software you already use, so your team can do the job you hired them for.

Every letter by dateHow this database is built

FDA Warning Letter Alerts

Share this view

Send the same filters, search and view to a colleague.

You choose what to post or send. Sharing a link does not change access to this site.